文献速递淋巴瘤

B细胞淋巴瘤中频繁的ZNF217突变通过改变染色质可及性导致干扰素信号转导的转录失调

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
PubMed 文献 · Leukemia · 2023-08-30

在157例原发纵隔B细胞淋巴瘤(PMBCL)患者中,33%存在ZNF217遗传病变;基因表达谱(n=120)显示ZNF217异常病例的细胞因子和干扰素信号转导发生改变。体外敲除ZNF217改变染色质可及性,干扰淋巴瘤相关转录因子结合基序,导致干扰素应答和炎症相关基因表达紊乱、细胞行为改变及分化异常。质谱显示ZNF217作用于含LSD1、CoREST和HDAC的组蛋白修饰复合体,干扰H3K4甲基化和H3K27乙酰化。

要点

  • 33%的PMBCL患者(157例中)存在ZNF217遗传病变。
  • ZNF217异常PMBCL病例(n=120)显示细胞因子和干扰素信号转导改变。
  • ZNF217通过含LSD1、CoREST和HDAC的组蛋白修饰复合体干扰H3K4甲基化和H3K27乙酰化。

核心结论

  • 数据提示ZNF217具有非催化活性,指导组蛋白修饰复合体功能并控制B细胞分化相关的染色质结构模式。

研究设计与样本

  • 靶向测序检测157例PMBCL患者的ZNF217遗传病变;对120例进行基因表达谱分析;体外敲除ZNF217研究染色质可及性和基因表达;质谱鉴定ZNF217相互作用的组蛋白修饰复合体。

主要发现

  • 靶向测序发现157例PMBCL患者中33%存在ZNF217遗传病变。
  • 基因表达谱(n=120)显示ZNF217异常PMBCL病例的细胞因子和干扰素信号转导发生改变。
  • 体外敲除ZNF217导致染色质可及性改变,干扰关键淋巴瘤相关转录因子的结合基序。
  • 敲除ZNF217导致干扰素应答和炎症相关基因表达紊乱、细胞行为改变及分化异常。
  • 质谱显示ZNF217作用于含LSD1、CoREST和HDAC的组蛋白修饰复合体,干扰H3K4甲基化和H3K27乙酰化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequencing identified genetic lesions affecting ZNF217 in 33% of 157 PMBCL patients. Subsequent gene expression profiling (n = 120) revealed changes in cytokine and interferon signal transduction in ZNF217-aberrant PMBCL cases. In vitro, knockout of ZNF217 led to changes in chromatin accessibility interfering with binding motifs for crucial lymphoma-associated transcription factors. This led to disturbed expression of interferon-responsive and inflammation-associated genes, altered cell behavior, and aberrant differentiation. Mass spectrometry demonstrates that ZNF217 acts within a histone modifier complex containing LSD1, CoREST and HDAC and interferes with H3K4 methylation and H3K27 acetylation. Concluding, our data suggest non-catalytic activity of ZNF217, which directs histone modifier complex function and controls B cell differentiation-associated patterns of chromatin structure.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Briest F, Noerenberg D, Hennch C, et al. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Leukemia. 2023. PMID: 37648814. doi:10.1038/s41375-023-02013-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。